BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The company is headquartered in Modiin, Central(Hamerkaz) and currently employs 24 full-time employees. The company went IPO on 2007-01-30. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
BLRX stock price ended at $3.35 on 水曜日, after rising 10.20%
On the latest trading day May 06, 2026, the stock price of BLRX rose by 10.20%, climbing from $3.03 to $3.35. During the session, the stock saw a volatility of 15.77%, with prices oscillating between a daily low of $2.98 and a high of $3.45. Notably, trading volume dropped by 62.3K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 71.9K shares were traded, equating to a market value of approximately $14.5M.